On 19 JUNE BlackBerry Ltd (NASDAQ:BBRY) announced that BlackBerry Ltd (NASDAQ:BBRY)’s newly-appointed CEO, John Chen, took over responsibility to turn around the company in November last year. At that time he believed there was a 50% chance of a turnaround; last month Chen improved the odds to 80%. He has targeted to bring the company to profits by the end of FY16.BlackBerry Ltd (NASDAQ:BBRY) net profit margin is -6.73% and weekly performance is 24.33%. On last trading day company shares ended up $9.81. Analysts mean target price for the company is $10.90. BlackBerry Ltd (NASDAQ:BBRY) distance from 50-day simple moving average (SMA50) is 29.64%.
On 20 JUNE Molycorp Inc (NYSE:MCP)’s CEO Geoffrey Bedford, said that increasing equity could help the company diminish its failure to generate free cash flow. Last year, the company had reported free cash flow that is the money it makes from its various operations, exclusive of capital expenses, was negative 4533.7 million. Molycorp Inc (NYSE:MCP) shares fell -4.42% in last trading session and ended the day on $2.81. MCP Gross Margin is -16.30% and its return on assets is -15.80%. Molycorp Inc (NYSE:MCP) quarterly performance is -44.25%.
On 16 JUNE Northwest Biotherapeutics, Inc (NASDAQ:NWBO) announced that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have received 4 of the 6 planned injections are showing tumor cell death, tumor shrinkage, substantial immune cell accumulation in their tumors and/or stabilization of their advanced cancer. In addition, in 3 of these 9 patients, biopsies now show no live tumor cells in the injected tumor. The company plans to report more details when the patients are further along in the treatment regimen. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) shares moved up 3.62% in last trading session and was closed at $7.44, while trading in range of $3.10 – $10.64. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) year to date (YTD) performance is 97.35%.
On 18 JUNE ReneSola Ltd. (ADR) (NYSE:SOL) announced that Solar Insurance & Finance (“Solarif”), an international and independent insurance broker specializing in insurance for PV installations, has certified ReneSola modules based on a positive audit of the Company involving relevant technical, financial, environmental, and labor considerations. As a result, ReneSola customers who choose to insure their PV projects through Solarif are eligible for additional coverage that extends the warranty to include inherent defects. ReneSola Ltd. (ADR) (NYSE:SOL) ended the last trading day at $3.14. Company weekly volatility is calculated as 7.45% and price to cash ratio as 3.68. ReneSola Ltd. (ADR) (NYSE:SOL) showed a positive weekly performance of 22.66%.
StemCells Inc (NASDAQ:STEM) announced that, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration or AMD for focussing its attention on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. StemCells Inc (NASDAQ:STEM) weekly performance is 40.79%. On last trading day company shares ended up $2.14. Analysts mean target price for the company is $4.00. StemCells Inc (NASDAQ:STEM) distance from 50-day simple moving average (SMA50) is 58.40%.
Leave a Reply